BMY Stock Analysis — AI Buy/Sell Signals & Forecast
Real-time AI-powered analysis for BMY with price targets, technical indicators (RSI, MACD, SMA), institutional money flow, and news-based signals.
Unlock Full Pro Analysis
Real-time alerts, price targets, institutional flow & more — one-time $19.95.
BMY · Bristol-Myers Squibb Company
Free summary — full analysis below.
Bristol-Myers Squibb Company
Pre-Market & After Hours is Pro Only
Upgrade to unlock this and all premium features
Oct 8, 05:26 AM
Confidence Score is Pro Only
Upgrade to unlock this and all premium features
Optimal Buy & Sell Zones is Pro Only
Upgrade to unlock this and all premium features
Pullback in Uptrend — Below SMA50 but above SMA200
Total Conviction Scorecard is Pro Only
Upgrade to unlock this and all premium features
Optimal Buy & Sell Zones is Pro Only
Upgrade to unlock this and all premium features
$-8.94 (-13.0%) from high
Day's Range: $59.01 – $60.10
+$17.18 (+40.4%) above low
▼ Below — short-term downtrend (bearish)
▲ Above — long-term uptrend (bullish)
✓ 0.9x avg — normal activity, signals are reliable
✓ Normal — healthy trading conditions
RSI, MACD & SMA based on daily closes — update at market close. Live price shown separately.
Institutional Money Flow is Pro Only
Upgrade to unlock this and all premium features
Phantom Flow is Pro Only
Upgrade to unlock this and all premium features
Smart Money Flow Index is Pro Only
Upgrade to unlock this and all premium features
Risk Score is Pro Only
Upgrade to unlock this and all premium features
Bristol Myers Squibb offers strong dividend reliability and promising growth potential from key assets like Reblozyl. Recent positive sentiment and slight price target increases suggest the stock is undervalued for long-term income investors.
Latest News & Market Impact
2 High-Yield Stocks to Buy in October (Hint: Bristol Myers Squibb Is One)
Is Exelixis Stock Engineered To Make You Money?
Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?
Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong
Disclaimer: This analysis is AI-generated and should not be considered financial advice. Always consult a qualified financial advisor before making investment decisions.
BMY Stock Analysis — Frequently Asked Questions
Is BMY a buy or sell right now?▾
Our AI engine analyzes BMY across technicals (RSI, MACD, SMA50/200), institutional money flow (OBV, SEC 13D/13G filings), news sentiment, and price action to produce a real-time buy/sell signal with a confidence score. The recommendation updates every time the analysis runs.
What is the price target for BMY?▾
The analysis calculates optimal entry and exit price targets for BMY using support/resistance levels, moving-average structure, and momentum. These levels are dynamic and recompute as new market data arrives.
What do the RSI and MACD signals say about BMY?▾
RSI measures whether BMY is overbought or oversold; MACD shows momentum and trend shifts. A bullish MACD crossover with RSI below 70 often signals continued upside, while divergence can warn of a reversal.
Are institutions buying BMY?▾
We track institutional positioning in BMY through On-Balance Volume (OBV) money flow and SEC Schedule 13D/13G filings — the same disclosures activist investors and large funds must file. Rising OBV plus new 13D filings typically indicate smart-money accumulation.
What are the main risks of investing in BMY?▾
Key risks for BMY include valuation compression, sector rotation, earnings volatility, and macro factors such as rates and inflation. The analysis grades risk from very low to very high based on volatility, drawdown history, and beta.
How accurate is the BMY AI analysis?▾
The BMY analysis combines real-time market data, technical indicators, institutional flow, and news-based sentiment. It is a decision-support tool, not financial advice — always do your own research and consider your risk tolerance before investing.
Market Intelligence provides AI-powered stock & ETF analysis for informational purposes only and does not constitute financial advice.